Endocrinology Research and Practice
Orijinal Araştırma

Evaluation of Galectin-3 in Graves’ Disease With and Without Ophthalmopathy


Department of Internal Medicine, Harran University, School of Medicine, Şanlıurfa, Turkey


Department of Endocrinology, Harran University, School of Medicine, Şanlıurfa, Turkey


Harran University, School of Medicine, Department of Clinical Biochemistry, Şanlıurfa, Turkey

Endocrinol Res Pract 2023; 27: 85-88
DOI: 10.5152/tjem.2022.173
Okunma: 561 İndirilme: 209 Online Yayın Tarihi: 24 Nisan 2023

Objective: There is a link between thyroid-associated ophthalmopathy and Graves’ disease; however,  the exact pathophysiological mechanism remains unclear. Galectin-3 expressed by immune and inflammatory cells plays a role in various vital cellular functions as well as supports angiogenesis and fibroblastic activity. The role of Galectin-3 in thyroid-associated ophthalmopathy has not been studied yet, so we aimed to evaluate the alteration of Galectin-3 level in thyroidassociated ophthalmopathy.

Methods: This cross-sectional descriptive study was conducted from May 2018 to April 2020. This study consisted of 63 participants, who were divided into 3 groups: group 1 was composed of 21  patients with Graves’ disease with thyroid-associated ophthalmopathy, group 2 consisted of 21  patients with Graves’ disease without orbitopathy, and group 3 consisted of 21 healthy individuals.

Results: Although the mean Galectin-3 levels in group 1 (8.6 ± 4.1 ng/mL) and group 2 (7.1 ± 5.4 ng/mL) were higher than group 3 (3.7 ± 2.8 ng/mL), there was no significant difference in Galectin-3 levels between groups 1 and 2 (P=.001 and P=.030, respectively). In Pearson’s correlation analyses, there was a significantly positive correlation between Galectin-3 and thyroid-stimulating hormone (r=0.452, P=.003) and a negative correlation between Galectin-3 and thyrotropin receptor autoantibody (r=–.318, P=.040).

Conclusion: In this study, it is shown for the first time that Galectin-3 levels are higher in patients with Graves’ disease than in healthy individuals. Increasing Galectin-3 levels may trigger autoimmunity or may lead to the development of thyroid hyperplasia. Although Galectin-3 level was found to be high in patients with Graves, we did not find any relationship between Galectin-3 and thyroid-associated ophthalmopathy.

Cite this article as: Akın M, Karaaslan H, Ali Eren M, Koyuncu İ, Sabuncu T. Evaluation of galectin-3 in graves’ disease with and without ophthalmopathy. Endocrinol Res Pract. 2023;27(2):85-88.

EISSN 2822-6135